0000880771-17-000061.txt : 20170323 0000880771-17-000061.hdr.sgml : 20170323 20170323164403 ACCESSION NUMBER: 0000880771-17-000061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170321 FILED AS OF DATE: 20170323 DATE AS OF CHANGE: 20170323 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 17710166 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2017-03-21 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2017-03-21 4 M 0 30338 3.55 A 122864 D Common Stock 2017-03-21 4 S 0 30338 9.5094 D 92526 D Common Stock 2017-03-22 4 M 0 9662 3.55 A 102188 D Common Stock 2017-03-22 4 S 0 9662 9.3279 D 92526 D Non-Qualified Stock Options (right to buy) 3.55 2017-03-21 4 M 0 30338 0 D 2020-03-05 Common Stock 30338 260062 D Non-Qualified Stock Options (right to buy) 3.55 2017-03-22 4 M 0 9662 0 D 2020-03-05 Common Stock 9662 250400 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016. Granted under the Issuer's 2005 Equity Incentive Plan. 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. /s/ Friedhelm Blobel, Ph.D. 2017-03-23